Breast Cancer
EU Focus Meeting 2026
📍 SANA Malhoa Hotel, Av. José Malhoa 8, 1099-089 Lisbon, Portugal
🗓️ September 25 - 26, 2026
Last Year's Highlights
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the Breast Cancer Focus Meeting 2026, to be held at on September 25 - 26, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Breast Cancer research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of Breast Cancer EU Focus Meeting 2026:
Javier Cortes, MD, PhD
University Hospital Vall d’Hebron, Barcelona, Spain
Virginia Kaklamani, MD, PhD
UT Health, San Antonio, TX
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
cristina.anton@md-education.com
Agenda & Faculty
Friday, 25 September, 2026 | Day 1
Session I: Updates in HER2 Positive Breast Cancer
Moderated by:
TBD
TBD
KOL TBD
09:05 AM
How to Optimize Regimens in the Adjuvant Setting
Sara M. Tolaney, MD
Dana Farber Cancer Institute, Boston, MA
09:25 AM
Treatment Landscape in Metastatic HER2 Positive Breast Cancer
Javier Cortes, MD
International Breast Cancer Center (IBCC), Barcelona, and IOB Madrid, Spain
09:45 AM
Novel Anti HER2 Agents
Ian Krop, MD
Yale School of Medicine, New Haven, CT
Session II: Local Therapy
Moderated by:
TBD
TBD
TBD
10:45 AM
Postmastectomy Radiation
PP
Philip Poortmans, MD
University of Antwerp, Belgium
11:05 AM
Can we Omit SLN Altogether?
ITR
Isabel T. Rubio, MD
Clínica Universidad de Navarra, Spain
11:25 AM
Can we Avoid Radiation For Low Risk DCIS
IM
Icro Meattini, MD
University of Florence, Italy
Session III: Risk Reduction and Early Detection
Moderated by:
TBD
TBD
TBD
01:40 PM
Risk Models
GE
Gareth Evans, MD
The Christie Private Care, Manchester, UK
02:00 PM
Optimal Risk Reducing Management for BRCA1/2 Carriers
ML
Matteo Lambertini, MD
University of Genova, Italy
02:20 PM
What’s New on Chemoprevention?
SK
Seema Khan, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
Session IV: HR+ Early Stage Breast Cancer
Moderated by:
TBD
TBD
TBD
04:05 PM
Who Needs OFS?
OP
Olivia Pagani, MD
Hopital Riviera-Chablais, Vaud, Switzerland
04:25 PM
Use of Genomic Tools to Help with Chemotherapy Decisions
AL
Antonio Llombart, MD
University Hospital Arnau de Vilanova, Lleida, Spain
04:45 PM
Optimizing Endocrine Therapy in Early Stage Breast Cancer
TBD
TBD
TBD
Saturday, 26 September, 2026 | Day 2
Session V: Triple Negative Breast Cancer
Moderated by:
TBD
TBD
KOL TBD
09:05 AM
How to Address High Risk TNBC
RD
Rebecca Dent, MD
National Cancer Centre Singapore, Singapore
09:25 AM
MRD: Should We Use it in Clinic?
MI
Michail Ignatiades, MD
Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Belgium
09:45 AM
How Can We Define Low Risk TNBC
MK
Marleene Kok, MD
Netherlands Cancer Institute, Amsterdam, Netherlands
Session VI: Breast Cancer: Difficult to Treat Situations
Moderated by:
TBD
TBD
KOL TBD
10:45 AM
CNS Metastases
RB
Rupert Bartsch, MD
Medical University of Vienna, Austria
11:05 AM
Oligometastatic Breast Cancer
BP
Barbara Pistilli, MD
Gustave Roussy Institute, Villejuif, France
11:25 AM
Anthracyclines en eBC
PS
Priyanka Sharma, MD
University of Kansas Medical Center, Kansas City, KS
Session VII: HR+ Metastatic Breast Cancer
Moderated by:
TBD
TBD
KOL TBD
01:40 PM
What is the Optimal First-line Strategy?
KJ
Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York, NY
02:00 PM
How to Treat MBC Beyond CDK 4/6 Inhibitors
VK
Virginia Kaklamani, MD
UT Health, San Antonio, TX
02:20 PM
The Future of ADCs in HR+ MBC
TBD
TBD
TBD
Session VIII: ADCs in MBC: How to Optimize the Right Strategy
Moderated by:
TBD
TBD
KOL TBD
04:05 PM
Mechanisms of Resistance to ADCs
BP
Barbara Pistilli, MD
Gustave Roussy Institute, Villejuif, France
04:25 PM
Sequencing ADCs in Clinical Practice
TBD
TBD
TBD
04:45 PM
The Future of ADCs: New Payloads, New Targets
HR
Hope Rugo, MD
UCSF Health, San Francisco, CA
Charlotte Pilling
Project Manager
How long has Charlotte Pilling been in the business?
Charlotte Pilling has been with MD Education since 2024.
About Charlotte Pilling
As Assistant Project Manager at our Wigan office, I draw on my extensive background in customer-facing roles to ensure smooth communication and successful project delivery. With over 14 years of experience in customer service, I've built a strong foundation in client relations, problem-solving, and team coordination. My attention to detail, proactive approach, and passion for excellence are qualities I bring to every project, and I'm dedicated to supporting project teams.
